Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merrimack Pharmaceuticals has dosed first patient in a Phase 2 clinical trial of MM-121, in combination with erlotinib (Tarceva) for the treatment of metastatic non-small cell lung cancer (NSCLC).
Subscribe to our email newsletter
MM-121 is a fully human monoclonal antibody that targets ErbB3, while erlotinib (Tarceva) is a small molecule directed at the epidermal growth factor receptor (EGFR).
The study is intended to determine Progression Free Survival (PFS) when combining MM-121 and erlotinib in three distinct metastatic NSCLC patient populations including Group A, Group B and Group C.
The patients in Group A do not have an EGFR activating mutation in their tumors and will be randomized to receive either MM-121 in combination with erlotinib or erlotinib alone.
Group B patients’ tumors have an EGFR activating mutation and will be randomized to receive either MM-121 in combination with erlotinib or erlotinib alone.
Group C that will receive MM-121 in combination with erlotinib, includes patients whose tumors had responded to EGFR targeted therapy and subsequently acquired resistance.